Channel Therapeutics Corporation (CHRO) AMEX
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.26 |
| Open | 1.25 |
| Day High | 1.48 |
| Day Low | 1.23 |
| 52-Week High | 54.29 |
| 52-Week Low | 1.23 |
| Volume | 193,120 |
| Average Volume | 111,305 |
| Market Cap | 8.9M |
| PE | -0.11 |
| EPS | -12 |
| Moving Average 50 Days | 12.03 |
| Moving Average 200 Days | 12 |
| Change | 0.09 |
Data not available
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
GlobeNewswire Inc.
Jul 02, 2025 11:00 AM GMT
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
GlobeNewswire Inc.
Jun 27, 2025 1:15 PM GMT
FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one r
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
Global Chronic Ocular Pain Market Valued at US$ 7.2 Billion in 2023 and Is Projected To Reach US$ 12.44 Billion by 2032 at a CAGR of 6.6% During Forecast Period 2024–2032FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporat